Real-Time Transrectal Ultrasound-Based Planning for High Dose-Rate Brachytherapy Boost in Intermediate and High Risk Prostate Cancer

2017 American Brachytherapy Society’s Annual Meeting Report

“…And finally, in the fourth award recipient's presentation investigators discussed that the incomplete PET/CT response rate in cervical cancer patients was documented in 17% of centrally reviewed patients following MRI based brachytherapy for cervical cancer (4). Results showed that the false positive rate of PET-IR was 74%, and integration of functional MRI helped further differentiate true positives from false positives (4 The Annual Meeting also featured the work of Pearse et al, who investigated and found the use of real time transrectal ultrasound-based planning for high doserate brachytherapy boost, using a 15 Gy implant, for intermediate and high-risk prostate cancer is associated with favorable outcomes (Figure 2) (6). The group's findings are in line with the results of their previous study for intermediate risk patients (6).…”

“…Results showed that the false positive rate of PET-IR was 74%, and integration of functional MRI helped further differentiate true positives from false positives (4 The Annual Meeting also featured the work of Pearse et al, who investigated and found the use of real time transrectal ultrasound-based planning for high doserate brachytherapy boost, using a 15 Gy implant, for intermediate and high-risk prostate cancer is associated with favorable outcomes (Figure 2) (6). The group's findings are in line with the results of their previous study for intermediate risk patients (6). All et al sought to determine that feasibility and outcomes of MRI-Based planning for high dose rate (HDR) brachytherapy for prostate cancer (7).…”